SparX Group Announces First Patient Dosed with SPX-303 Injec

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

/PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been...

Related Keywords

Phoenix , Arizona , United States , Chicago , Illinois , University Of Arizona , Dong Zhu , Justin Moser , Sparx Biopharmaceutical Corp , Sparx Group , Research Institute , Honorhealth Research Institute , University Of Arizona College Medicine , Gui Dong Zhu , Chief Executive Officer , Arizona College , Sparx Biopharmaceutical , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,